

PREVENTION & THERAPIES FOR HEPATITIS AND CHRONIC LIVER DISEASE

Denver, CO – April 30, 2022

**Conference
Location**

Curtis Hotel
1405 Curtis Street
Denver CO 80202

Phone: (303) 571-0300

[https:// hilton.com/en/hotels/denchdt-the-curtis-denver/?SEO_id=GMB-DT-DENCHDT](https://hilton.com/en/hotels/denchdt-the-curtis-denver/?SEO_id=GMB-DT-DENCHDT)

**Parking at the
Seminar**

A reduced daily parking rate of \$10 has been arranged for you. Please bring the parking ticket to the registration desk

**Driving
Directions**

From I-75 and I-25.

- Take I-25 South to Exit 210A (US-40/ US 287/Colfax Avenue)
- Use the middle lane to turn left on E/W Colfax Avenue
- Use the right lane to take and Aurora Parkway and Ramp to I-25 N to Ft Collins; Stay left to keep on Aurora Parkway
- Continue onto Market Street and then Right at 14th Street. Turn Left at Curtis Street and hotel is on the left.

**Seminar Agenda
and Syllabus
Information**

Registration begins at **7:00 am** in the **Peek-a-boo Room (2nd floor)**. Please check signage for any last-minute room changes.

The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. Wi-Fi will be available without charge.

A limited number of guest rooms has been reserved on Friday night at a rate of \$159 plus taxes

Pre-Program Activities	Lecture 1 – Viral Hepatitis –A summary for discovery and natural history of HCV 60 min Lecture 2 - End Stage Liver Disease: An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
7:00am	Registration and View Exhibits
7:30 am	Opening Comments and Pre-Test
7:45 am	Hepatitis C: Update on Diagnostics <ul style="list-style-type: none"> • Short recap of key points from Pre-course lecture on viral hepatitis • Screening and diagnostic approaches of HCV Hepatitis C: Update on Treatment <ul style="list-style-type: none"> • AASLD/IDSA Guidelines and Updates • Simplified Guidance Case Studies 1 and 2 –New Case relevant to diagnosis and treatment of high-risk HCV patient
8:35am	Hepatitis B: Epidemiology, Natural History and Testing <ul style="list-style-type: none"> • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • The growing relationship between HBV and HDV
9:05 am	Anti-viral Therapies for HBV <ul style="list-style-type: none"> • Early detection and treatment approaches • Treating HCC in patients with Hepatitis B • Reactivation of HVB

9:35 am	Industry Presentation #1 Break and View exhibits
10:15 am	Delta Hepatitis and Hepatitis E Update <ul style="list-style-type: none"> Worldwide perspective and promising research studies Real world outcome studies on HDV and HEV
10:45 am	End Stage Liver Disease: Recap and Clinical Case <ul style="list-style-type: none"> A review of Pre-course lecture touching on staging, work-up and remedies for cirrhosis and the liver transplant process
11:15 am	Alcoholic Liver Disease <ul style="list-style-type: none"> The growing prevalence of alcohol over-consumption and its impact on liver health Warning signs and intervention in alcoholic hepatitis
11:45 am	Hepatocellular Carcinoma (HCC) <ul style="list-style-type: none"> Screening diagnostic serum assays and imaging tests Treatment and management options: Ablation, TACE and Surgery
12:15 pm	Luncheon and Industry Presentation #2
1:00pm	Dessert and View Exhibits
1:10 pm	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> Current FDA-Approved Therapies New chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC Case Study 3– Diagnosis and Treatment of Hepatocellular Carcinoma
1:40 pm	SARS-COV-2 in Liver Disease <ul style="list-style-type: none"> Effect of COVID on the liver and in cirrhotic patients COVID-19 challenges for liver transplant recipients
2:10pm	Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis <ul style="list-style-type: none"> Epidemiology of PSC and Ursodiol and Antibiotic Treatments Predicting outcomes and Improving Survival in PSC patients Causes and Markers of PBC Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
2:45 pm	<ul style="list-style-type: none"> Break & View Exhibits
3:00 pm	NAFLD and NASH <ul style="list-style-type: none"> Epidemiology, Demographics and Diagnosis Scoring, Staging and Management of Fatty Liver Disease Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
3:35 pm	NASH Treatments in Practice and in Development <ul style="list-style-type: none"> Current therapies for NASH including Updates from AASLD and EASL Lifestyle changes as a therapy Drugs in clinical development for NASH
4:25 pm	Closing Comments, Post-test and Wrap-Up Program adjourns at 4:45 pm
Post-program activities	Lecture 3 - Viral Hepatitis Updates: The reemergence of Hepatitis A and Overcoming barriers to liver health in special populations - 60 minutes

**Attendance
Policies**

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

**CME
Information**

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)™**.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1264. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)™ organizations accredited by ACCME.

**Your
Seminar
Faculty**



LISA M. FORMAN, MD

Lisa Forman is an Associate Professor, Medicine- in the Division of Gastroenterology at the University of Colorado School of Medicine. She received her medical degree the University of Pennsylvania, where she also completed her residency and Fellowship in Gastroenterology.

Dr. Forman's primary clinical interests include NASH, HCV, hepatic encephalopathy, liver transplantation, and metabolic complications after liver transplantation. She is Board Certified in Gastroenterology and Transplant Hepatology.



AVASH KARLA, MD

Avash Kalra is a Transplant Hepatologist and Assistant Professor of Medicine at the University of Colorado, where he also serves as Director of Liver Transplant Outreach and Strategic Development. He specializes in the evidence-based care of adult patients with liver disease. Prior to medical school, Dr. Kalra graduated from Cornell University and subsequently worked as a research assistant at the National Institutes of Health (NIH). During his training, he was recognized with the Gold Foundation Humanism and Excellence in Teaching Award. Academically, Dr. Kalra has published

numerous scientific research manuscripts and has authored several review articles and textbook chapters. He is an active member of the American Association for the Study of Liver Disease (AASLD).

In addition to caring for patients at the University of Colorado, Dr. Kalra is licensed in the states of Montana, Wyoming and New Mexico, where he is establishing outreach clinics.



MICHAEL BALL, PharmD

Michael Ball is a Clinical Pharmacy Specialist at the Presbyterian/St. Luke's Transplant Center. His role spans from the intensive care unit to the ambulatory clinic, where he also provides treatment for hepatitis C virus patients under a collaborative practice agreement with Dr. Clark Kulig.

He attended pharmacy school at the University of Colorado Denver Skaggs School of Pharmacy and Pharmaceutical Sciences, followed by a PGY1 Pharmacy Practice residency at Presbyterian/St. Luke's Medical Center and a PGY2 Solid Organ Transplant residency at Children's Healthcare of Atlanta. Dr. Ball is an active member of the American College of Clinical Pharmacy (ACCP) and the American Society of Transplantation (AST).